(CercleFinance.com) – Eli Lilly announces positive initial results from its SURMOUNT-OSA phase III clinical trials, which showed that tirzepatide injection significantly reduced the apnea-hypopnea index (AHI) compared to placebo .
Tirzepatide achieved an average AHI reduction of up to 63% (approximately 30 fewer events per hour), meeting all key primary and secondary endpoints in two Phase III clinical trials.
More broadly, the product significantly improved symptoms in people with moderate to severe obstructive sleep apnea and obesity with and without positive airway pressure treatment.
Copyright © 2024 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
